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  Brucellosis affects at different species of animals and is zoonotic for humans. Vaccines are based on live attenuated bacteria and animals develop the same antibodies being impossible to distinguish serologically vaccinated animals from infected1. Acute phase proteins (APPs), used 
as biomarkers2, could be useful to solve this problem. THE AIM OF THIS WORK is to characterize the APPs response in mice infected with B. 
melitensis 16M or vaccinated with Rev1 to detect biomarkers differentiating between two conditions.  
MATERIALS and METHODS 
Kinetics of infection. Female balb/c mice (4 per lot) were intraperitoneally (ip) injected with 104 colony forming units (CFU) of B. melitensis 16M or with the vaccine strain 
Rev1. Rev1 was also subcutaneously (sc) injected at 105 CFU since it is the standard route and dose for vaccine administration. Control mice were ip injected with PBS. 
Weight and CFU from liver and spleen were determined at 7, 14, 21, 28 and 56 days. In vitro studies. Serum concentration of serum amyloid A (SAA), α-1 glycoprotein acid 
(AGP), haptoglobin (HPT) and hemopexin (HPX) were measured by ELISA. Liver and spleen mRNA relative units (RU) of this APPs were determined by qPCR. All data are 
represented as Mean+SEM and were analysed using independent samples t-Test with SPSS 16.0. *p<0.05, **p<0.01, ***p<0.001.  
RESULTS and DISCUSSION 
Differences were found in APPs serum concentration among mice injected with B. 
melitensis 16M, Rev1 ip and Rev1 sc. These differences were also reflected in liver 
mRNA levels of these proteins.  
Peaking on day 14, AGP, HPT and HPX serum concentration were greater in mice 
injected with Rev1 ip, intermediate with B. melitensis 16M and similar to control 
with Rev1 sc. The peak of SAA was also reached on day 14 for mice inoculated 
with Rev1 ip, but did it earlier (day 7) for mice inoculated with B. melitensis 16M. 
These SAA values were higher than those for Rev1 on day 3 (sc) and 7 (ip or sc) 
(Figure 1).  
APPs serum concentration values were in agreement with spleen and liver 
inflammation (weight) caused by any of these inoculations. Maximum CFU values 
were reached before of those of inflammation, being 1.5 fold lower for Rev1 sc 
(Table 1). 
APPs gene expression was upregulated in liver and downregulated in spleen, 
except for SAA in the latter. Time-course of liver APPs gene expression was 
peaked on day 14 (or day 7 for B. melitensis 16M). Mice inoculated with Rev1 sc 
showed a high level of APPs mRNA that did not correspond to the protein 
concentration in serum. This effect was more evident for HPX (Figure 2). Thus, 
Rev1 sc inoculation could cause protein malformations or inhibition of the APPs 
secretion mechanism by liver. Spleen did not contribute to mRNA synthesis of 
APPs except for SAA. AGP, HPT and HPX were downregulated on day 7 post-
inoculation. A recovery of their expression was observed at 14-21 days, except for 
those injected with B. melitensis 16M (Figure 3). 
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Spleen  Time post-inoculation 3 days 7 days 14 days 21 days 28 days 56 days 
log CFU 
B. melitensis 16M 5.19+0.07 6.27+0.07 5.00+0.11 4.73+0.12 4.66+0.39 3.55+0.52 
Rev1 ip 4.71+0.12 6.53+0.06 5.65+0.16 4.87+0.18 3.42+0.36 2.93+0.61 
Rev1 sc 1.20+0.71 3.45+0.58 4.40+0.42 3.67+0.72 2.69+0.69 0.00+0.00 
g 
B. melitensis 16M 0.14+0.01 0.23+0.02 0.31+0.04 0.25+0.02 0.22+0.02 0.15+0.01 
Rev1 ip 0.11+0.01 0.12+0.01 0.45+0.04 0.33+0.06 0.21+0.01 0.20+0.01 
Rev1 sc 0.11+0.11 0.14+0.14 0.20+0.03 0.17+0.02 0.17+0.02 0.13+0.01 
Liver  Time post-inoculation 3 days 7 days 14 days 21 days 28 days 56 days 
log CFU 
B. melitensis 16M 4.72+0.06 4.79+0.07 3.15+0.16 2.54+0.29 2.25+0.79 0.99+0.57 
Rev1 ip 4.78+0.07 4.81+0.17 3.02+0.26 2.34+0.78 1.43+0.52 0.36+0.36 
Rev1 sc 0.48+0.48 2.64+0.29 2.90+0.14 1.72+0.62 1.48+0.60 0.56+0.56 
g 
B. melitensis 16M 1.10+0.09 1.41+0.05 1.20+0.11 1.38+0.06 1.36+0.05 1.34+0.14 
Rev1 ip 1.09+0.08 1.06+0.03 1.52+0.06 1.40+0.09 1.24+0.06 1.33+0.07 
Rev1 sc 1.14+0.07 1.11+0.05 1.20+0.07 0.94+0.11 1.00+0.06 1.22+0.06 
Figure 1. Time-course of serum concentration of SAA, AGP, HPT and HPX. Mean+SEM; n=4. 
*/**/*** vs Rev1 ip; */**/*** vs Rev1 sc. 
 
 
 
Table 1. Number of Brucella (CFU) and liver and spleen weight (g). Mean+SEM; n=4. 
Figure 2. Time-course of liver mRNA level of SAA, AGP, HPT and HPX. Mean+SEM; n=2.  
Figure 3. Time-course of spleen mRNA level of SAA, AGP, HPT and HPX. Two separate animals. 
CONCLUSION: APPs show great promise as biomarkers to differentiate between Brucella melitensis infected and vaccinated animals. 
Specifically, HPT and HPX during medium term and SAA during the early stage of Brucella-induced inflammation. 
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